{"url":"https://newsforagent.com/news/2026-11-16/johnson-johnson-ollin-biosciences-acquisition","markdown_url":"https://newsforagent.com/news/2026-11-16/johnson-johnson-ollin-biosciences-acquisition.md","title":"Johnson & Johnson Eyes Ollin Biosciences in $3.4 Billion Deal","headline":"Johnson & Johnson Weighs Up to $3.4 Billion Purchase of Eye Disease Biotech Ollin Biosciences","description":"Johnson & Johnson is considering buying Ollin Biosciences for up to $3.4 billion, with $2.2 billion upfront in cash and $1.2 billion in milestone payments.","section":"Mergers & Acquisitions","published_at":"2026-11-16T00:54:41+00:00","modified_at":"2026-11-16T00:54:41+00:00","author":"News Desk","key_takeaways":["Johnson & Johnson is looking to acquire Ollin Biosciences for up to $3.4 billion, per the Financial Times.","The structure calls for $2.2 billion upfront in cash and up to $1.2 billion in potential milestone payments.","Ollin Biosciences reported JADE trial results comparing OLN324 to faricimab at EURETINA 2026 in Vienna."],"companies":[{"name":"Johnson & Johnson Services, Inc.","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc","website":"https://www.jnj.com"},{"name":"Ollin Biosciences","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00004dt/ollin-biosciences","website":"https://ollin.bio"}],"source":{"publisher":"The future of trading","title":"Johnson & Johnson Looking To Buy Eye Disease Biotech Ollin Biosciences For Up To $3.4 Billion - FT","url":"https://capital.com/en-int/news/johnson-johnson-looking-to-buy-eye-disease-biotech-ollin"},"other_sources":[],"tags":["Mergers & Acquisitions","Johnson & Johnson Services, Inc.","Ollin Biosciences"],"body_markdown":"[Johnson](https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc) & Johnson is looking to buy eye disease biotech [Ollin Biosciences](https://akta.pro/company-profiles/00004dt/ollin-biosciences) for up to $3.4 billion, [The future of trading](https://capital.com/en-int/news/johnson-johnson-looking-to-buy-eye-disease-biotech-ollin) reported, citing the Financial Times. The structure would pay Ollin's backers $2.2 billion upfront in cash and a further $1.2 billion in potential milestone payments.\n\n## Inside the J&J and Ollin Deal Terms\n\nThe reported consideration totals up to $3.4 billion, split between $2.2 billion in cash at the outset and up to $1.2 billion tied to potential milestone payments. The report did not state a signing date, a closing date or any regulatory conditions.\n\nJohnson & Johnson is the New Brunswick-based pharmaceutical and medical technology group led by chairman and chief executive Joaquin Duato, according to company records. Ollin Biosciences is an ophthalmology biotech whose OLN324 candidate has been studied in diabetic macular edema and wet age-related macular degeneration, according to company records.\n\nOllin Biosciences said it would present JADE trial results comparing OLN324 to faricimab at EURETINA 2026 in Vienna, held October 1-4, 2026, [BioSpace](https://akta.pro/news-signals) reported. The trial showed OLN324 achieved faster and greater anatomic outcomes in diabetic macular edema and wet AMD, according to the same report.\n\n## Johnson & Johnson's Recent Acquisition Record\n\nJohnson & Johnson's recent deal history includes a roughly $1 billion acquisition of Firefly Bio, announced in June 2026, to gain degrader antibody conjugate technology targeting KRAS-driven tumors, according to akta.pro [company records](https://akta.pro/company-data). The company also announced a $3.05 billion acquisition of Halda Therapeutics in November 2025 to add RIPTAC therapies and the HLD-0915 candidate targeting metastatic castration-resistant prostate cancer, the same records show.\n\nJohnson & Johnson completed its $14.6 billion acquisition of Intra-Cellular Therapies in January 2025, expanding its neuroscience and CNS pipeline, according to the same records. The company reported $94.2 billion in revenue for fiscal 2025 with 6% growth and net income of $26.8 billion.\n\n## Carvykti Sales and Pipeline Updates\n\nJohnson & Johnson and Legend Biotech reported $710 million in net revenue from Carvykti in the third quarter of 2026, a 36% increase, with international sales up 86%, FinanzNachrichten.de reported in November 2026. The same report said Mesoblast presented a new CAR-MSC platform targeting inflammatory diseases such as lupus and IBD, with no clinical data yet.\n\nJohnson & Johnson reported $74.8 billion in sales for the first nine months of 2026, up 7.4% year over year, The Motley Fool reported in November 2026. The company expects double-digit growth by 2030, citing new drugs such as Icotyde and a proposed $5.5 billion talc settlement, according to the same report.\n\nIşıl Çelik joined Johnson & Johnson as Head of HR for Surgery Emerging Markets and Aesthetics & Reconstruction EMEA, Hrtoday reported in November 2026, covering the Middle East, Africa, Central Eastern Europe, Türkiye, Russia and CIS.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}